Community post

Adaptive Phage Therapeutics announced a strategic agreement with the Antibacterial Resistance Leadership Group to support a phase 1b/2 cystic fibrosis (CF) study. The randomized, double-blind, placebo-controlled trial will assess the safety and microbiological activity of a single dose of phage therapy in cystic fibrosis subjects colonized with Pseudomonas aeruginosa.